Literature DB >> 28864891

Cytotoxicity of targeted HER2-specific phototoxins based on flavoprotein miniSOG is determined by the rate of their internalization.

O N Shilova1, G M Proshkina2, A V Ryabova3, S M Deyev2, R V Petrov2.   

Abstract

The concept of targeted therapy implies the development of bifunctional agents complementing the therapeutic module with a targeting one. A promising target for the delivery of imaging and/or toxic modules is the HER2 (ErbB2) receptor. Earlier, we have functionally characterized the targeted photosensitizers 4D5scFv-miniSOG and DARPin-miniSOG, causing the death of HER2-overexpressing cells when irradiated with blue light. However, the cytotoxicity of targeted toxins 4D5scFv-miniSOG and DARPin-miniSOG (both having functionally active targeted and cytotoxic modules in recombinant proteins) against human breast adenocarcinoma cells differs 5 times. The study of the dynamics of internalization of 4D5scFv-miniSOG and DARPin-miniSOG proteins in the complex with HER2 in this work showed that the rate of internalization contributes most significantly to the toxicity of these photosensitizers, because it determines the duration of the presence of the phototoxin in the lipid bilayer of the cell membrane, where its damaging effect is maximum.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28864891     DOI: 10.1134/S1607672917040044

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  14 in total

1.  A new anticancer toxin based on HER2/neu-specific DARPin and photoactive flavoprotein miniSOG.

Authors:  G M Proshkina; O N Shilova; A V Ryabova; O A Stremovskiy; S M Deyev
Journal:  Biochimie       Date:  2015-08-28       Impact factor: 4.079

2.  Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments.

Authors:  Gianluca Interlandi; Svava K Wetzel; Giovanni Settanni; Andreas Plückthun; Amedeo Caflisch
Journal:  J Mol Biol       Date:  2007-09-21       Impact factor: 5.469

3.  First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Authors:  Gideon M Blumenthal; Nancy S Scher; Patricia Cortazar; Somesh Chattopadhyay; Shenghui Tang; Pengfei Song; Qi Liu; Kimberly Ringgold; Anne M Pilaro; Amy Tilley; Kathryn E King; Laurie Graham; Barbara L Rellahan; Wendy C Weinberg; Bo Chi; Colleen Thomas; Patricia Hughes; Amna Ibrahim; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2013-06-25       Impact factor: 12.531

Review 4.  A decade of tyrosine kinases: from gene discovery to therapeutics.

Authors:  Rolf J Craven; Harry Lightfoot; William G Cance
Journal:  Surg Oncol       Date:  2003-07       Impact factor: 3.279

Review 5.  Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms.

Authors:  A W Girotti
Journal:  J Photochem Photobiol B       Date:  2001-10       Impact factor: 6.252

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.

Authors:  E A Sokolova; T A Zdobnova; O A Stremovskiy; I V Balalaeva; S M Deyev
Journal:  Biochemistry (Mosc)       Date:  2014-12       Impact factor: 2.824

8.  Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.

Authors:  Evgeniya Sokolova; Galina Proshkina; Olga Kutova; Olga Shilova; Anastasiya Ryabova; Alexey Schulga; Oleg Stremovskiy; Tatiana Zdobnova; Irina Balalaeva; Sergey Deyev
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 11.467

9.  Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.

Authors:  Kristina E Mironova; Galina M Proshkina; Anastasiya V Ryabova; Oleg A Stremovskiy; Sergey A Lukyanov; Rem V Petrov; Sergey M Deyev
Journal:  Theranostics       Date:  2013-10-12       Impact factor: 11.556

10.  A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.

Authors:  Tatiana Zdobnova; Evgeniya Sokolova; Oleg Stremovskiy; Dmitry Karpenko; William Telford; Ilya Turchin; Irina Balalaeva; Sergey Deyev
Journal:  Oncotarget       Date:  2015-10-13
View more
  4 in total

1.  The Application of Recombinant Phototoxins 4D5scFv-miniSOG and DARPin-miniSOG to Study the HER2 Receptor Internalization.

Authors:  E O Kuzichkina; O N Shilova; S M Deyev; R V Petrov
Journal:  Dokl Biochem Biophys       Date:  2018-11-05       Impact factor: 0.788

2.  The Mechanism of Fluorescence Quenching of Protein Photosensitizers Based on miniSOG During Internalization of the HER2 Receptor.

Authors:  E O Kuzichkina; O N Shilova; S M Deyev
Journal:  Acta Naturae       Date:  2018 Oct-Dec       Impact factor: 1.845

Review 3.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

4.  UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer.

Authors:  Evgenii L Guryev; Anita S Smyshlyaeva; Natalia Y Shilyagina; Evgeniya A Sokolova; Samah Shanwar; Alexey B Kostyuk; Alexander V Lyubeshkin; Alexey A Schulga; Elena V Konovalova; Quan Lin; Indrajit Roy; Irina V Balalaeva; Sergey M Deyev; Andrei V Zvyagin
Journal:  Molecules       Date:  2020-09-19       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.